Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 Jun 16;100(13):7797–7802. doi: 10.1073/pnas.1330920100

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003, The National Academy of Sciences

PMC Copyright notice

Fig. 4. — Application of caspase 8 siRNA leads to significantly improved survival in different models of ALF. Prevention of Fas (CD95)-mediated apoptosis by caspase 8 siRNA was investigated by application of caspase 8 siRNA or scrambled siRNA 48 h before administration of Jo2 or AdFasL. Control animals received Jo2 or AdFasL without siRNA treatment. (a) Whereas all animals with unprotected livers died, prevention of apoptosis by caspase 8 siRNA led to 100% survival in AdFasL-mediated liver failure and 45% survival in Jo2-mediated ALF. (b) Therapeutic intervention by RNAi in an ongoing ALF was investigated by application of caspase 8 siRNA after viral liver infection with AdFasL or Adwt. Increase of transaminases (serum alanine aminotransferase and serum aspartate transaminase) demonstrates liver injury already 4 and 8 h after application of Adwt. Treatment with caspase 8 siRNA 8 h after application of AdFasL or Adwt significantly improves survival of animals. Control animals received AdFasL or Adwt without siRNA treatment.